Vietnam's next-generation sequencing (NGS) market is poised for significant expansion as the country accelerates investment in precision medicine, cancer diagnostics, genomics research and biotechnology.
Industry analysis indicates the market is projected to reach US$50–70 million by 2030 reflecting increasing adoption of genomic technologies across healthcare, research and pharmaceutical development, supported by broader growth across the Asia-Pacific region.
The wider Asia-Pacific NGS market is forecast to grow to US$7.38 billion by 2030, at a CAGR of 16.7%, fuelled by expanding applications in oncology, rare disease diagnostics, infectious disease surveillance and precision medicine programmes.
Several factors are driving demand for NGS technologies in Vietnam, including:
- Increasing use of genomic sequencing in precision oncology and companion diagnostics.
- Growing adoption of non-invasive prenatal testing (NIPT) and inherited disease screening.
- Expansion of pharmaceutical and biotechnology research and development.
- Falling sequencing costs, making genomic testing more accessible.
- Rising investment in molecular diagnostics, personalised medicine and clinical research.
- Greater collaboration between Vietnamese healthcare institutions and international genomics companies.
The market is expected to benefit from continued advances in sequencing platforms, bioinformatics and artificial intelligence, enabling laboratories to deliver faster, more accurate and more cost-effective genomic analysis. As Vietnam strengthens its healthcare infrastructure and life sciences capabilities, NGS is becoming an increasingly important tool in cancer care, infectious disease surveillance, reproductive health and translational research.
Leading global suppliers including Illumina, Thermo Fisher Scientific, Roche, BGI Genomics and QIAGEN continue to expand their presence across Southeast Asia, supporting the adoption of sequencing technologies through partnerships with hospitals, research institutes and diagnostic laboratories.
For companies operating in genomics, molecular diagnostics, laboratory technology and biotechnology, Vietnam represents one of Southeast Asia's most promising emerging markets, offering substantial opportunities as precision medicine becomes an increasingly integral part of clinical care.
